Chronic rhinosinusitis and asthma: novel understanding of the role of IgE 'above atopy'.
Chronic rhinosinusitis (CRS) affects more than 10% of the European population and is often associated with asthma. Phenotypes of CRS can be differentiated based on mucosal remodelling and inflammatory patterns. Understanding the role of central mediators, such as interleukin-5, in these different phenotypes may lead to the development of specific therapeutic approaches. The impact of staphylococcal superantigens has been shown to further modify the immune response, contributing to persistent severe disease via the activation of T and B cells and the formation of local IgE. It is clear that these mechanisms are involved in the systemic spread of upper airway disease with resulting asthma comorbidity, when IgE antibodies to staphylococcal enterotoxins are present at measurable levels in serum. Recent findings point to superantigens as possible causal agents in the intrinsic form of severe asthma, and an anti-IgE strategy has shown promising therapeutic potential in nonatopic patients with nasal polyps and asthma. These findings should lead to a clinically relevant endotyping of patients with upper and lower airway disease and to a new understanding of the role of IgE 'above atopy'.
Upper Airway Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, Ghent, Belgium. claus.bachert@ugent.be
C
C
Bachert
N
N
Zhang
D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001249:Asthma / Q000097:blood / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D015415:Biomarkers; D002908:Chronic Disease; D006801:Humans; D007073:Immunoglobulin E / Q000378:metabolism*; D007155:Immunologic Factors / Q000627:therapeutic use; D007249:Inflammation / Q000276:immunology / Q000503:physiopathology; D015848:Interleukin-5 / Q000378:metabolism; D009297:Nasal Mucosa / Q000276:immunology / Q000503:physiopathology; D009298:Nasal Polyps / Q000209:etiology / Q000503:physiopathology; D010641:Phenotype; D016032:Randomized Controlled Trials as Topic; D012220:Rhinitis / Q000209:etiology / Q000503:physiopathology; D012852:Sinusitis / Q000209:etiology / Q000503:physiopathology; D013211:Staphylococcus aureus / Q000276:immunology*; D018089:Superantigens / Q000097:blood*
D061067:Antibodies, Monoclonal, Humanized; D015415:Biomarkers; D007155:Immunologic Factors; D015848:Interleukin-5; D018089:Superantigens; D007073:Immunoglobulin E; C434107:mepolizumab